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Summary
Transcatheter (or percutaneous) renal denervation is a nov-
el technique developed for the treatment of resistant hy-
pertension. So far, only one randomised controlled trial
has been published, which has shown a reduction of office
blood pressure. The Swiss Society of Hypertension, the
Swiss Society of Cardiology, The Swiss Society of Angi-
ology and the Swiss Society of Interventional Radiology
decided to establish recommendations to practicing physi-
cians and specialists for good clinical practice. The eligib-
ility of patients for trancatheter renal denervation needs (1.)
confirmation of truly resistant hypertension, (2.) exclusion
of secondary forms of hypertension, (3.) a multidisciplin-
ary decision confirming the eligibility, (4.) facilities that
guarantee procedural safety and (5.) a long-term follow-
up of the patients, if possible in cooperation with a hyper-
tension specialist. These steps are essential until long-term
data on safety and efficacy are available.
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Introduction
Arterial hypertension (HTN) is the most common cardi-
ovascular risk factor. A recent nationwide cross-sectional
study showed that the overall prevalence of HTN in adults
is 26% (32% in men and 19% in women) [1]. In patients
over 60 years of age the prevalence reaches 65% in men
and 53% in women. In patients with hypertension, it is
estimated that 10% to 30% have resistant hypertension
(rHTN), defined as an uncontrolled office blood pressure
(BP) – systolic BP ≥140 mm Hg and/or diastolic BP ≥90
mm Hg – despite the use of three antihypertensive drugs,
including a diuretic, at adequate doses [2, 3]. In a retro-
spective study, 2% of patients with a new diagnosis of HTN
developed rHTN within 2 years [4]. The identification of
patients with rHTN is essential, since such patients have
a 50% increase in risk of cardiovascular events compared
with the usual hypertensive population [4].
Transcatheter (or percutaneous) renal denervation (RDN) is
a novel technique developed for the treatment of rHTN. So
far, several pilot trials and one randomised controlled tri-
al have shown a significant reduction in office BP in a se-
lected group of patients with rHTN [5]. The technique has
been available in Switzerland since 2010. The principle of
the method is the thermic neurolysis of renal efferent and
afferent sympathetic nerve fibres located in the adventitia
of renal arteries by applying a low intensity radiofrequency
within the main trunk of renal arteries.
Although expert statements of members of the European
Society of Cardiology and the European Society of Hyper-
tension have been published, no specific recommendations
are currently available for the good clinical use of this
technique in Switzerland [6–8]. With the introduction of
renal denervation in the Swiss diagnosis related groups
(DRG) catalogue of reimbursed procedures, the Swiss So-
ciety of Hypertension, the Swiss Society of Cardiology, the
Swiss Society of Angiology and the Swiss Society of In-
terventional Radiology have decided to establish recom-
mendations on renal denervation for practicing physicians
and cardiovascular specialists based on currently available
evidence.
This document summarises the current state of knowledge
and proposes practical recommendations for the treatment
of patients with rHTN. As with all recommendations, res-
ults from ongoing and new clinical trials and devices are
likely to change these recommendations in the near future.
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 7
Pathophysiology and rationale for
renal denervation
The kidneys play a pivotal role in the homeostasis of water
and electrolytes, and hence in the long-term control of BP.
They are innervated by afferent (from the kidney to the
brain) and efferent sympathetic nerves (from the medulla
oblongata to the kidneys) that contribute to both the devel-
opment and the maintenance of HTN [9]. An increased ef-
ferent renal sympathetic nerve activity leads to: (1.) stim-
ulation of renin release in juxtaglomerular cells thereby
leading to enhanced angiotensin II production, (2.) renal
vasoconstriction leading to reduced renal blood flow and
(3.) increased renal tubular sodium reabsorption leading to
sodium retention. Each of these renal functional alterations
can decrease renal excretory function and thus affect long-
term control of BP [10]. Increased renal sympathetic nerve
activity is present in most forms of animal and human HTN
and is, therefore, a logical target for HTN treatment [9].
Technique of catheter-based renal
denervation
The procedure is currently performed under local anaes-
thesia via femoral access, although radial systems are under
development. Since the ablation procedure itself is asso-
ciated with severe pain during the application of radiofre-
quency energy, systematic pain management is mandatory
(usually with fentanyl derivatives). Furthermore, vital signs
should be closely monitored during the procedure. Finally,
aspirin (either prior chronic use of 100 mg/day or else
500 mg acetylsalicic acid i.v.) plus 5,000 IU unfractionated
heparin i.v. is recommended prior to RDN as thrombus
formation has been documented after the procedure [11].
Currently, more than a dozen RDN catheters and ablation
systems have been developed. Novel multi-electrode sys-
tems will become available soon. In order to use a device in
clinical practice, safety and efficacy of the ablation system
has to be proven and the device has to be CE marked.
The devices that have obtained the CE label (conform to all
applicable European Community directives) and are avail-
able in Switzerland are shown in table 1.
With any system, at the end of the procedure renal angio-
grams should be performed in order to detect any – al-
beit rare – potential procedure-related complication, such
as renal artery dissection or severe spasm. Renal artery dis-
section can generally be treated immediately with the im-
plantation of a stent. The puncture site must be checked for
bleeding before discharge.
The procedure can be performed either during a 24-hour
hospitalisation or on an outpatient basis. Indeed, as BP
decreases very slowly and continuously over weeks and
months, hypotension after the procedure (with the excep-
tion of vagal reactions during sheet removal) are rare. Anti-
hypertensive treatment should not be interrupted immedi-
ately after renal denervation, since blood pressure lowering
effects are delayed and the maximum effect is expected
after 3 to 6 months.
Efficacy: current evidence for
transcatheter renal denervation
So far, only one multicentre randomised controlled trial
(RCT) has been conducted, as well as four case control
studies and a growing number of case series [3, 5, 12,
Table 1: Types of renal denervation devices.
Device Provider Technology Vascular access Duration
Symplicity Medtronic Single electorde, monopolar, non-
irrigated
6F introducer 2 min / ablation point
EnligHTN St-Jude Medical Multi-electrode basket, monopolar
non-irrigated
8F introducer 90 sec/point
Vessix Boston Scientifc Over the wire balloon-based
irrigated catheter, bipolar
8F introducer 30 sec/artery
Covidien ballon Covidien Over the wire balloon-based
irrigated catheter, monopolar
7-8F introducer 2 min/artery
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13]. The single RCT currently available included 106 pa-
tients randomised in a non-blinded fashion, 52 patients in
the RDN group and 54 patients in the control group (Sym-
plicity HTN-2). The primary efficacy endpoint was the
between-group change in average office-based measure-
ments of systolic BP from baseline to 6 months after ran-
domisation [5]. The results showed an office-based systolic
and diastolic BP reduction in the RDN group of 32/12 mm
Hg (standard deviation [SD] 23/11 mm Hg, baseline BP
178/96 mm Hg, p <0.001), whereas no significant change
(1/0 mm Hg) from baseline was observed in the control
group (SD 21/10 mm Hg], baseline BP 178/97 mm Hg).
The primary endpoint was reached as between-group dif-
ferences in BP at month 6 reached 33/11 mm Hg (p
<0.001). However, as with any antihypertensive interven-
tion, when 24-hour BP was measured using ambulatory BP
monitoring (ABPM), renal denervation-induced changes in
BP were less pronounced (–10.2 mm Hg in systolic BP
and –4.9 mm Hg in diastolic BP at 6 months) [14, 15].
The lesser effect seen in ambulatory BP compared with of-
fice BP has been confirmed in a subject-level meta-ana-
lysis [16]. Interestingly, renal denervation had no effect in
patients with pseudo-resistant HTN, defined as mean am-
bulatory 24-hour systolic BP <130 mm Hg despite elevated
office systolic BP readings [15]. Data from the Symplicity
programme confirm that the reduction in blood pressure
progresses further up to 24 months after RDN without any
change in renal function [17, 18]. In a small randomised
study using the St. Jude Basket Ablation catheter, similar
reductions of BP after 6 months were found [19].
A double-blind randomised controlled trial with a sham
procedure is currently ongoing in the United States and has
completed recruitment of over 300 patients [20]. In this
study, changes in office BP remain the primary endpoint,
but the changes in ambulatory BP at 6 months have been
included as a secondary endpoint.
Beyond BP lowering, exploratory studies suggest that
RDN exerts a variety of potentially important protective
effects, such as an improvement in insulin resistance, left
ventricular hypertrophy and diastolic function of the left
ventricle [21–23]. Whether or not such surrogate endpoints
will translate into a reduction of major adverse cardiovas-
cular events beyond BP reduction will have to be con-
firmed in large randomised clinical trials. Indeed, St. Jude
has announced a prospective randomised study enrolling
more than 4,000 high risk patients with HTN that will start
later this year.
Safety of transcatheter renal
denervation
Bradycardia requiring atropine administration was reported
in the Symplicity HTN-1 study in seven out of 52 patients
[12]. Reported procedure-related and/or device-related
complications are rare and include renal artery dissection
(one case in the Symplicity HTN-1), pseudoaneurysm of
the femoral artery at the puncture site (one case in the Sym-
plicity HTN-1, and one in the Symplicity 2 study) [5, 12].
Late complications may include renal artery stenosis (one
case observed at the 24-month follow-up of a cohort in-
cluding 153 patients treated in an open-label study) [24,
25].
Recently, optical coherence tomography (OCT) was used
to assess renal vascular damage [11]. Immediately after the
procedure, local intimal oedema formation, de-endotheli-
alisation, intimal detachment and thrombus formation was
visible. Furthermore, upon 3D reconstruction, mean renal
artery diameter is reduced by around 20% with a typical
“string-of-bead” appearance reflecting diffuse spasm.
Whether and to what degree such changes are reversible re-
mains to be determined.
Overall renal function, assessed by estimated glomerular
filtration rate (eGFR), remained stable in all studies. In 88
patients treated by renal denervation, no significant change
in glomerular filtration rate was observed 6 months after
the procedure and a decreased incidence of albuminuria
was reported 6 months after the intervention [26].
No data exists regarding long-term safety (beyond 3 years),
and the limited number of patients included in studies or
with a systematic follow-up cannot rule out major occa-
sional complications. Accordingly, regular clinical and
imaging monitoring of patients who have had transcatheter
RDN is recommended. It is also advised that any device-
related complication/dysfunction should be reported to the
national materiovigilance authorities (Swissmedic).
Safety issues not directly related to the procedure include
the use of radiological contrast agents (i.e. contrast-induced
renal dysfunction) and the use of anaesthesia. Contrast-in-
duced kidney injury is usually transient except in patients
with a very low glomerular filtration rate. Anaesthesia is
required because of the severe pain transmitted centrally by
the afferent renal nerves. In general a fentanyl derivative is
used.
Current limitations of transcatheter
renal denervation
Several limitations regarding the studies published so far
must be mentioned.
1. Clinical evaluation-related issues:
a) Number of patients included in controlled studies is
limited.
b) Follow-up period is limited.
c) No consistent optimal medical treatment (three
drugs at full dose including a diuretic) was used.
d) Office BP was used as primary endpoint.
2. Device/technology-related issues:
a) Lack of any periprocedural marker that might
identify good responders or success of therapy (other
than changes in BP after the procedure).
b) The current spot strategy application of
radiofrequency energy in the renal artery is empirical
as regards both the number and sites used.
Recommendations
Diagnosis and work-up of resistant hypertension
So far, renal denervation is only indicated for the treatment
of resistant hypertension. The rationale for a systematic
work-up of candidates for the procedure (fig. 1) is to as-
Review article Swiss Med Wkly. 2014;144:w13913
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 7
certain the diagnosis in order to identify patients at high
cardiovascular risk and to exclude secondary causes of
hypertension, which are more frequent in truly resistant
hypertension and which may require specific treatment.
Therefore, the initial management includes:
1. Confirmation of true treatment resistance:
a) Use of a correct BP measurement technique.
Rationale: inappropriate technique, material or setting
may overestimate or underestimate BP [27].
b) Exclusion of white-coat hypertension (ABPM;
home BP measurements).
Rationale: white-coat hypertension may be present in
up to 30% of apparently resistant hypertensive patients
[28].
c) Assessment of adherence to treatment (adherence
history, pill count, follow-up of prescriptions renewal,
electronic monitoring) and counselling of patients
appropriately [29].
Rationale: up to 30% with apparent resistant
hypertension may not have a good adherence to
treatement [30].
d) Correction of lifestyle factors with negative impact
on BP (high sodium diet, alcohol, physical inactivity).
e) Optimal use of triple drug therapy at maximum
tolerated doses (ideally a diuretic, a calcium-channel
blocker and a blocker of the renin-angiotensin system).
Rationale: inadequate treatment is a frequent cause of
apparent resistant hypertension [31].
f) Use of a loop diuretic in stage 4 chronic kidney
disease (eGFR <30 ml/min/1.73 m2).
g) Addition of a mineralocorticoid receptor or another
class of antihypertensive, if tolerated, after exclusion
of a secondary cause.
h) Discontinuation or minimal use of interfering
substances (nonsteroidal anti-inflammatory drugs,
liquorice, oral contraceptives...).
i) Screen for secondary cause of hypertension:
– chronic kidney disease;
– primary aldosteronism;
– sleep apnoea syndrome,
– renal artery stenosis;
– phaeochromocytoma, paraganglioma, primary
hyperparathyroidism, thyroid dysfunction, Cushing’s
Figure 1
Suggested algorithm for the work-up before endovascular renal
denervation (RDN) in resistant hypertension (rHTN).
syndrome, aortic coarctation, intracranial tumour,
acromegaly (all uncommon)
Rationale: secondary causes of hypertension are more
prevalent in resistant hypertension than in essential
hypertension [32].
After this initial work-up, the decision to perform RDN
should be discussed by a multidisciplinary team in a spe-
cialised centre after imaging of the renal arteries (computed
tomography [CT] or magnetic resonance imaging) to assess
their number, length and diameter. These diagnostic steps
are essential since most patients are not eligible for renal
denervation according to strict inclusion and exclusion cri-
teria [33, 34]. The risk benefit ratio of the intervention
should be evaluated individually for each patient, taking in-
to account renal function and the patient’s preferences.
Indications for transcatheter renal denervation in 2013
Based on current knowledge, the Expert Consensus panel
limits the indication for transcatheter RDN to patients who
have:
1. Truly resistant hypertension confirmed with systolic
office BP >140 mm Hg and confirmed by daytime
ABPM (or home BP measurements) >135/85 mm Hg
or night time >120/70 mm Hg.
2. Intolerance to many antihypertensive drugs that impairs
adequate therapy.
3. Suitable renal artery anatomy.
4. Presence of two functioning kidneys with at least 90
mm bipolar length.
5. Decision taken by a multidisciplinary team.
6. Patient informed consent obtained, after an explanation
of the safety and efficacy of the procedure.
Based on current knowledge, the Expert Consensus panel
recommends not performing RDN in the following situ-
ations:
1. Patient under 18 years of age.
2. Prior renal stent or renal angioplasty.
3. Significant renal artery stenosis (>70%).
4. Renal artery fibromuscular dysplasia.
5. Heavily calcified plaques in the target segment of the
renal artery.
6. Extensive aortic and renal atherosclerotic disease.
7. eGFR <45 ml/min/1.73 m2.
8. Secondary forms of hypertension.
The recommendations do not apply to patients included in
clinical trial with specific inclusion and exclusion criteria.
Facilities and skills
The recommended facilities should include a well-trained
intervention team with at least:
1. One trained interventionist. A physician trained in RDN
who has an experience track record for renal artery
diagnostics and interventions, or five angioplasties of
the renal artery per year during the last five years.
2. Two assistants (nurse or physician) able to handle the
device and control appropriate sedation/anaesthesia.
The person in charge of device handling should have
received specific RDN training with practical training
on the device.
3. A dedicated and modern catheterisation laboratory with:
a) High-quality fluoroscopy (C-arms in an operating
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room are not sufficient).
b) An optimal acquisition system that can analyse the
angiogram at any time during the procedure,
specifically for ruling out acute complications.
c) Optimal radioprotection.
d) Equipment for monitoring haemodynamic pressure
and electrocardiographic activity.
e) Available equipment to handle potential
complications, such as resuscitation equipment
including an external cardiac defibrillator, or dedicated
equipment for percutaneous renal intervention
(including balloon, conventional and “covered”
stents).
Follow-up
RDN necessitates long-term follow-up by a hypertension
specialist, which should be organised before denervation.
This follow-up should include:
• Regular clinical visits to monitor office BP and to ad-
apt treatment.
• ABPM at months 3, 6, 12, 24 and whenever needed
if office BP is repeatedly uncontrolled.
• Regular testing of renal function (creatinine, albu-
minuria) at week 1 and 4, and every 6 months there-
after.
• Renal artery morphological assessment (preferably
with CT angiography or ultrasound) at 12 months
and 36 months.
• Renal radiological studies should be performed if
glomerular filtration rate declines by more than 20%
or if BP becomes resistant again.
• After the procedure antihypertensive therapy may
be progressively adjusted depending on the BP re-
sponse.
• Patients should be included in a registry.
Perspectives of transcatheter renal
denervation
Renal nerve ablation might have a role in other conditions
associated with increased sympathetic nerve activity.
Indeed, small trials suggest that the role of this new tech-
nique may not be limited to hypertension, but might be use-
ful also in chronic heart failure, chronic kidney disease and
renal failure, polycystic ovary syndrome, sleep breathing
disorders, obesity and metabolic syndrome. Future stud-
ies will have to explore these possibilities and confirm
the safety and the efficacy of renal nerve ablation beyond
rHTN in controlled trials.
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Figures (large format)
Figure 1
Suggested algorithm for the work-up before endovascular renal denervation (RDN) in resistant hypertension (rHTN).
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